What is it about?

Developing a new medicine is expensive and can take more than a decade. An alternative approach, known as drug repurposing, aims to identify new diseases that can be treated using medicines that are already approved or have been studied in clinical trials. Because these drugs already have known safety profiles, repurposing can significantly reduce the time and cost needed to develop new treatments. In this study, we developed Repurposing Drug Explorer (ReDEx), a user-friendly, web-based platform that helps researchers identify promising drug repurposing opportunities without requiring programming skills. ReDEx combines several complementary approaches, including chemical structure similarity, biological network analysis, drug-target interactions, and functional pathway analysis, within a single interactive environment. Users can investigate individual drugs, diseases, or drug–disease pairs and obtain ranked lists of potential therapeutic candidates together with the biological evidence supporting the predictions. To demonstrate its performance, we applied ReDEx to psychiatric disorders, including bipolar disorder. Even after deliberately removing several known bipolar disorder drugs from the reference dataset, the platform successfully rediscovered all of them among its highest-ranked candidates from more than 28,000 possible drugs. This demonstrates that ReDEx can effectively prioritize biologically relevant compounds while providing transparent explanations of the underlying molecular mechanisms. Available through the Enalos Cloud Platform, ReDEx makes advanced drug repurposing analyses accessible to researchers from many scientific disciplines.

Featured Image

Why is it important?

Drug repurposing has become one of the most promising strategies for accelerating the discovery of new treatments, particularly for complex diseases where effective therapies remain limited. However, many existing computational tools focus on only one aspect of the problem or require advanced bioinformatics expertise. ReDEx addresses these limitations by integrating chemical, biological, and network-based analyses into a single, easy-to-use platform that requires no programming experience. By making sophisticated drug repurposing methods accessible through a web interface, ReDEx enables a broader community of researchers, clinicians, and pharmaceutical scientists to generate and evaluate new therapeutic hypotheses more efficiently. The platform has the potential to support research in precision medicine, rare diseases, neurological and psychiatric disorders, and many other therapeutic areas, ultimately helping accelerate the identification of new treatment opportunities while reducing research costs and development time.

Perspectives

ReDEx represents an important step toward democratizing computational drug repurposing by bringing together diverse analytical methods within a single cloud-based platform. We believe that making these technologies accessible to researchers without computational expertise will encourage wider adoption of in silico approaches during the early stages of drug discovery. Future versions of ReDEx will continue to expand with additional datasets, prediction algorithms, and artificial intelligence methods, allowing users to investigate a broader range of diseases and therapeutic questions. We hope the platform will serve as a valuable resource for both academic and industrial researchers, accelerating hypothesis generation, supporting experimental validation, and ultimately contributing to the development of more effective and personalized therapies.

Dr Antreas Afantitis
NovaMechanics Ltd

Read the Original

This page is a summary of: Repurposing Drug Explorer (ReDEx): A Tool for Integrating Disease Networks, Drug Similarity Algorithms and Functional Exploration Powered by Enalos Cloud Platform, Journal of Molecular Biology, December 2025, Elsevier,
DOI: 10.1016/j.jmb.2025.169610.
You can read the full text:

Read

Contributors

The following have contributed to this page